Navidea Biopharmaceuticals, Inc. Navidea Biopharmaceuticals, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Careers
  • Technology
    • Overview
    • Grant Funding
  • Pipeline
  • News & Media
    • Press Releases
    • Events
    • Publications
    • In the News
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News / Events
    • Presentations
    • Overview
    • Press Releases
    • IR Calendar
    • Safe Harbor Statement
    • Email Alerts
  • Company Info
    • Overview
    • Profile
    • Management Team
    • Contacts
  • Financial Info
    • Overview
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
  • Stock Data
    • Overview
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
  • News / Events

  • Presentations
  • Overview
  • Press Releases
  • IR Calendar
  • Safe Harbor Statement
  • Email Alerts

Navidea Biopharmaceuticals Announces Changes to Board of Directors Composition

May 5, 2021

Navidea Biopharmaceuticals to Host First Quarter 2021 Earnings Conference Call and Corporate Update

May 4, 2021

Navidea Biopharmaceuticals Announces Acceptance of Therapeutics Focused Abstract for Presentation at the Frontiers in Cancer Immunotherapy Symposium

Apr 15, 2021

Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results

Mar 24, 2021

Navidea Biopharmaceuticals to Host Fourth Quarter 2020 Earnings Conference Call and Corporate Update

Mar 17, 2021

Navidea Biopharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Virtual Conference

Mar 2, 2021

Navidea Biopharmaceuticals Announces $5 Million Private Placement with Existing Investor

Mar 2, 2021

Navidea Biopharmaceuticals Announces Submission of Formal Type B Meeting Request with FDA and Launch of NAV3-32 Phase 2B Trial in Rheumatoid Arthritis

Feb 8, 2021

Navidea Biopharmaceuticals to Present at the 2021 ICR Conference On January 14, 2021

Jan 7, 2021

Navidea Biopharmaceuticals Strengthens Board of Directors with the Appointment of Malcolm Witter

Dec 28, 2020
RSS
    • 1...
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • ...45
    © 2025 Navidea Biopharmaceuticals, Inc. All Rights Reserved.
    linkedin
    Privacy Policy Disclaimer Sitemap